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ABSTRACT
About 20% hepatocellular carcinomas (HCCs) display wild-type β-catenin, 
enhanced Wnt signaling, hepatocyte dedifferentiation and bad outcome, suggesting 
a specific impact of Wnt signals on HCC stem/progenitor cells. To study Wnt-specific 
molecular pathways, cell fates and clinical outcome, we fine-tuned Wnt/β-catenin 
signaling in liver progenitor cells, using the prototypical Wnt ligand Wnt3a. Cell biology 
assays and transcriptomic profiling were performed in HepaRG hepatic progenitors 
exposed to Wnt3a after β-catenin knockdown or Wnt inhibition with FZD8_CRD. Gene 
expression network, molecular pathology and survival analyses were performed on 
HCCs and matching non-tumor livers from 70 patients by real-time PCR and tissue 
micro-array-based immunohistochemistry. Wnt3a reprogrammed liver progenitors to 
replicating fibrogenic myofibroblast-like cells displaying stem and invasive features. 
Invasion was inhibited by 30 nM FZD7 and FZD8 CRDs. Translation of these data to 
human HCCs revealed two tight gene networks associating cell surface Wnt signaling, 
stem/progenitor markers and mesenchymal commitment. Both networks were linked 
by Hyaluronan And Proteoglycan Link Protein 1 (HAPLN1), that appeared de novo in 
aggressive HCCs expressing cytoplasmic β-catenin and stem cell markers. HAPLN1 was 
independently associated with bad overall and disease-free outcome. In vitro, HAPLN1 
was expressed de novo in EPCAM¯/NCAM+ mesoderm-committed progenitors, upon 
spontaneous epithelial-mesenchymal transition and de-differentiation of hepatocyte-
like cells to liver progenitors. In these cells, HAPLN1 knockdown downregulated 
key markers of mesenchymal cells, such as Snail, LGR5, collagen IV and α-SMA. In 
conclusion, HAPLN1 reflects a signaling network leading to stemness, mesenchymal 
commitment and HCC progression.
Oncotarget2www.impactjournals.com/oncotarget
INTRODUCTION
Approximately 20% of HCCs show activation 
of Wnt/β-catenin and TGFβ pathways, carry wild-type 
β-catenin, lose the hepatocyte phenotype and overexpress 
Frizzled (FZD) receptors [1, 2]. Wnt/β-catenin pathway 
activation involves interaction of Wnt ligands with 
cell surface FZD receptors and LRP5/6 co-receptors, 
followed by disruption of the Adenomatous polyposis 
coli (APC)-axin platform, thus halting GSK3B-dependent 
phosphorylation of β-catenin at key residues in exon 
3. Non-phosphorylated β-catenin is thus stabilized, 
accumulates in the cytoplasm and nucleus and interacts 
with T-cell factor (TCF) transcription factors of target 
gene expression. Conversely, in the absence of interaction 
of Wnt ligands with their cell surface receptors, 
phosphorylated β-catenin undergoes proteasomal 
degradation. β-catenin exon 3 mutations in tumors bypass 
the GSK3B gatekeeper, thus switching the pathway to the 
ON position constitutively [3]. 
It is widely accepted that Wnt pathway activation 
in HCCs may be driven by upregulation of TGFB and 
tyrosine-kinase receptor pathways [2, 4, 5], Wnt ligands, 
their cell surface frizzled receptors and/or epigenetic 
silencing of a family of endogenous Wnt inhibitors, i.e., 
the Secreted Frizzled-Related Proteins (SFRPs) [6]. SFRPs 
are soluble decoy receptors composed of a cysteine-rich 
frizzled ligand-binding domain (FZD_CRD), thereby 
quenching Wnt activity at the cell surface [7]. Thus, 
increasing the ratio of SFRP-like Wnt inhibitors over Wnt 
ligands or receptors controls tumor growth [8-11]. 
Most cases of HCC arise in a background of 
chronic inflammation and tissue remodeling, leading to 
stem/progenitor cell amplification [12]. In the context 
of experimental liver regeneration in response to tissue 
damage, Wnt signals expand transit-amplifying liver 
progenitor cells but impair hepatocyte differentiation 
[13].Thus, the aim of the present study was to investigate 
Wnt-specific molecular pathways, cell fates, phenotypes 
and clinical outcomes in HCC stem/progenitor cells. To 
this end, we fine-tuned Wnt/β-catenin signaling with the 
prototypical Wnt3a ligand [14, 15] and inhibited Wnt 
signaling using β-catenin siRNA knockdown or soluble 
FZD8_CRD in HepaRG liver progenitor cells. These 
bipotent progenitors carry wild-type Wnt/β-catenin 
pathway components [16] and can differentiate into 
hepatocyte- or biliary-like cells [17, 18]. 
We report that Wnt3a reprograms liver progenitors 
to replicating and invasive fibrogenic myofibroblast-like 
cells expressing stem cell markers. Analysis of HCCs 
from 70 patients revealed two tight gene networks 
associating stem/progenitor markers, cell surface Wnt 
signaling and fibrogenesis. Both networks were linked by 
Hyaluronan And Proteoglycan Link Protein 1 (HAPLN1), 
a mesenchymal matrix protein, which is essential in 
development [19]. HAPLN1 links proteoglycans with 
hyaluronic acid, thereby building growth factor binding 
platforms [20]. Whereas HAPLN1 appeared de novo 
in aggressive tumors expressing stem cell markers and 
in vitro models of epithelial-mesenchymal transition; 
HAPLN1 knockdown downregulated key markers of 
mesenchymal cells. We hypothesize that HAPLN1 can be 
hijacked by tumor evolution as a selective advantage for 
cancer progression. 
RESULTS
Wnt signals lead to myofibroblastic differentiation 
of liver progenitor cells
As Wnt3a binds frizzled (FZD) receptors at the 
low nanomolar range [3], HepaRG hepatic progenitor 
cells were incubated with Wnt3a-conditioned medium, 
which contains <10 nM Wnt3a [9] or with 7 nM 
purified recombinant Wnt3a for 13 days (Figure 
1A and Supplementary Figure 1A and 1B). Control 
media led differentiation to hepatocyte-like cells, as 
expected [18]. In contrast, Wnt3a-enriched media led to 
albumin¯ fibroblast-like cells, containing alpha-smooth-
muscle-actin+ (α-SMA+) stress fibers, thus indicating 
myofibroblast differentiation (Figure 1B). These cells 
expressed the basement membrane collagen type IV, the 
mesenchymal markers N-cadherin (Figure 1B), Vimentin 
and Fibronectin, as well as cytoplasmic β-catenin 
(Supplementary Figure 1C). Gene expression kinetics 
showed increased MYC, SNAI1, TWIST1 and TGFB1 
after 12 h, with a peak in Collagen IV and α-SMA mRNAs 
after 5 days of incubation of progenitor cells with purified 
Wnt3a. After 13 days, myofibroblast-like cells showed an 
important increase in LGR5 and BIRC5 (Survivin) and 
decrease in Aldolase B, GGT1, NOTCH2, Keratin 19 and 
SOX9 (Figure 1C). Consistently, after Wnt3a treatment, 
SNAI1 showed a seven-fold increase within the 1st h and 
CD44 increased within the first 8 h (Supplementary Figure 
1D). Wnt3a promoted Matrigel invasion, [inhibited by 30 
nM FZD7_CRD or FZD8_CRD (Figure 1D and 1E)], and 
cell proliferation throughout the 13-day assay (Figure 1F). 
Wnt signals promote commitment of transit-
amplifying liver progenitor cells to fibrogenic 
myofibroblast-like cells
To look at the gene networks leading to 
myofibroblastic differentiation of hepatic progenitors, we 
treated cells with 7 nM Wnt3a for three days. To identify 
β-catenin-dependent or FZD8_CRD sensitive gene 
networks, we transfected cells with β-catenin-targeting 
siRNA or treated them with the prototypical Wnt inhibitor 
FZD8_CRD. This strategy was validated by real-time PCR 
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Figure 1: Wnt signals differentiate liver progenitors to myofibroblast-like cells invading Matrigel. A. and B. Incubation 
of progenitor HepaRG cells with control or Wnt3a-conditioned medium for 13 days. A. Controls are hepatocyte-like. Cells incubated 
with Wnt3a are fibroblast-like. B. Coimmunodetection of the indicated proteins. Alpha smooth muscle actin (α-SMA), collagen IV and 
N-cadherin: green (FITC); albumin, red (FluoProbes 594); nuclei, blue (DAPI). Images were acquired with a Cellomics station at 20X. 
Wnt3a-incubated cells show bridging fascicules of spindle α-SMA(+)/albumin(-) cells. Stress fibers typical of myofibroblasts (white arrows) 
embrace foci of transitional elongated α-SMA(+)/albumin(+) cells (white arrowheads), with granular and filamentous compartments 
(yellow arrowheads). C. Gene expression kinetics of HepaRG cells incubated with recombinant Wnt3a or control BSA and analyzed by 
real-time PCR. D. FZD7_CRD and FZD8_CRD inhibit Wnt3a-induced Matrigel invasion. Cells were incubated in Matrigel-coated Boyden 
chambers with FCS(-) medium plus BSA; 7 nM Wnt3a; Wnt3a plus 30 nM FZD7 or FZD8_CRD. E. HepaRG cells invading Matrigel. F. 
Wnt3a enhances cell proliferation. Cells were incubated in 96-well plates with FCS(-) medium plus BSA or Wnt3a. BrdU(+) nuclei were 
counted with a Cellomics station. 
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gene expression analysis of the β-catenin target gene LGR5 
in HepaRG and Huh7 cells (Supplementary Figure 2A-
2D). A whole transcriptome analysis identified 358 genes 
differentially regulated by Wnt3a in progenitor HepaRG 
cells (Supplementary Figure 2E-2H and Supplementary 
Table 3A). After filtering out 169/358 genes affected by 
control (scrambled) siRNA (Supplementary Table 3B), 
we obtained 189 genes, 142 (75%) of them were sensitive 
to β-catenin siRNA knockdown and 47 (25%) were not 
(Supplementary Table 3, C and D). Among the 358 genes 
modulated by Wnt3a in HepaRG cells, 233 (65%) of them 
were inhibited by 30 nM FZD8_CRD and 125 (35%) were 
not (Supplementary Table 3, E and F). Finally, 77 genes 
were both sensitive to both β-catenin knockdown and 
FZD8_CRD in independent experiments (Supplementary 
Table 3G). 
Ingenuity Pathway Analysis revealed fibrogenesis 
and myofibroblast activation pathways (Figure 2A). 
Consistently, gene ontology analysis by FuncAssociate 2.0 
[21] confirmed that Wnt signals induced highly significant 
and reproducible fibrogenic gene sets (Supplementary 
Table 4). Also, gene ontology analysis confirmed that 
the gene set affected by scrambled siRNA was only 
associated with actin crosslink formation, reflecting 
cytoskeletal rearrangements following electroporation 
[22]. Importantly, genes specifically silenced by β-catenin 
targeting siRNA and by FZD8_CRD were both associated 
with fibrogenesis. 
To strengthen our observations, we compared the 
Wnt-induced signature in HepaRG cells with the whole 
genome mRNA expression profiles of epithelial 3P and 
fibroblast-like 3SP human HCC cell lines. These cells 
are derived from the same HCC, 3SP resulting from 
3P cells that underwent spontaneous EMT [23]. Gene 
Set Enrichment Analysis (GSEA) revealed that the 
transcriptome of 3SP cells was significantly enriched 
in genes induced by Wnt3a in HepaRG progenitor cells 
(Figure 2B). By hierarchical clustering, fibroblast-
like 3SP cells were unambiguously distinguished from 
epithelial 3P cells on the basis of the gene expression of 
Wnt Homepage targets (Figure 2C) and extracellular Wnt 
pathway components (Figure 2D) and associated functions 
Figure 2: Wnt signals activate a fibrogenic gene expression program in liver progenitors. A. Gene networks applying 
Ingenuity pathway analysis on the 358 gene set differentially regulated by Wnt3a. B. Wnt-induced differentiation of hepatic progenitors 
into fibrogenic myofibroblast-like cells matches the transcriptome signature of spontaneously emerging EMT in human HCC (GSE26391). 
3P and 3SP human HCC cell lines derive from the same tumor, mesenchymal 3SP resulting from epithelial 3P cells that underwent 
spontaneous EMT in a human HCC [23]. By gene set enrichment analysis, 3SP cells are significantly enriched in transcripts induced 
by Wnt3a in HepaRG cells. C. and D. Hierarchical clustering: 3SP and 3P cells are distinguished by C Wnt target genes from the Wnt 
Homepage (Supplementary Table 6A) and D Extracellular Wnt signaling (Wnt pathway ligands and receptors). Raw gene expression data 
were normalized by the Robust Multi-array Average (RMA) log2 algorithm and quantile filtered.
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(Supplementary Table 5). Moreover, comparison of the 
mRNA signature of transiently mesenchymal-competent 
cells induced by dedifferentiation of hepatocyte-like 
HepaRG cells [18] with our Wnt3a-induced signature 
confirmed that Wnt signals specifically promote 
differentiation of transit-amplifying liver progenitor cells 
to fibrogenic myofibroblast-like cells (Supplementary 
Table 6).
Figure 3: In vitro Wnt-induced fibrogenesis activates signaling networks that are functional in HCCs. A. RNA levels of 
the indicated genes in progenitor HepaRG HCC cells treated with Wnt3a after transfection with two β-catenin targeting siRNAs. B. LGR5 
mRNA expression in HepaRG and Huh-7 cells treated with BSA (control), the Hedgehog pathway inducer Purmorphamine, Wnt3a and the 
Hedgehog inhibitor KAAD-cyclopamine. Tomatidine is a cyclopamine structural analog which does not inhibit the Hedgehog pathway. 
C. Immunodetection of LGR5 in HepaRG cells after 13 days of incubation with Wnt3a or BSA. LGR5, red (FluoProbes 594); nuclei, blue 
(DAPI). D. RNA expression of the hepatocyte differentiation marker ALDOB in HepaRG cells transfected with LGR5 siRNA. E. Gene 
networks generated by Weighted Correlation Network Analysis (WGCNA) [44] using mRNA expression data for the indicated genes in 79 
HCCs. Networks with a correlation coefficient threshold ≥0.30 plotted with Cytoscape [45]. Closeness between nodes is proportional to 
the number of connections. Thickness of links is proportional to the correlation coefficients. F. 3D scatterplots showing the relationships 
between mRNA expression of the indicated genes in 79 HCCs. ACTA2, smooth muscle actin; COL4A1, procollagen, type IV, alpha 1 chain. 
Multiple regression coefficients (R) are indicated. 
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In vitro Wnt-induced fibrogenesis activates 
signaling networks that are functional in HCCs 
Close analysis of Wnt-induced genes sensitive 
to both β-catenin targeting siRNA and to FZD8_CRD 
(Supplementary Table 3G) revealed crosstalks of Wnt 
with TGFB/BMP, Notch, Hedgehog and IGF signaling 
pathways [5]. To validate these crosstalks, β-catenin 
dependency of representative genes of these four signaling 
pathways was confirmed by real-time PCR (Figure 3A). 
Among these, the induction of the stem cell marker 
LGR5 by Wnt3a in Huh-7 or HepaRG cells was partially 
inhibited by the Hedgehog inhibitor KAAD-cyclopamine, 
but not by the inactive structural analog tomatidine (Figure 
3B). Whereas LGR5 expression by myofibroblast-like 
cells suggested that they retained stem cell features (Figure 
3C); silencing of LGR5 by specific siRNA upregulated the 
hepatocyte differentiation marker aldolase B (Figure 3D), 
suggesting that Wnt-induced LGR5 impairs hepatocyte 
differentiation. 
We then sought to validate these findings in 79 
HCCs, by assessing the mRNA expression of the genes 
shown in Figure 3A-3C, together with genes involved in 
cell surface Wnt signaling (GPC3, SFRP1, SFRP2, DKK1, 
FZD1, FZD7, WNT2) and mesenchymal commitment 
(ACTA2, LAMC1; COL4A1). Of note, SFRPs 1 and 
2 also reflect mesenchymal commitment of stem cells 
[24]. Weighted Gene Co-expression Network Analysis 
revealed two tight networks associating stem/progenitor 
markers to cell surface Wnt signaling and mesenchymal 
commitment (Figure 3E and Supplementary Table 7). 
Both networks were linked by HAPLN1 and collagen IV 
(COL4A1). Hyaluronan And Proteoglycan Link Protein 1 
(HAPLN1) is a cartilage gene that links proteoglycans to 
hyaluronic acid, thereby playing a key role in extracellular 
matrix assembly [20]. While its absence leads to dwarfism 
[19], tumors de novo expresses HAPLN1 [25]. Multiple 
correlation analyses confirmed that both SFRP1 and 
HAPLN1 were associated with ACTA2 (α-SMA) and 
collagen type IV (Figure 3F). 
De novo expression of HAPLN1 hallmarks 
mesenchymal commitment 
Wnt3a-induced upregulation of HAPLN1 was 
first detected at 12 h (~2.5 fold) reaching >30 folds at 
13 days. At this time, HAPLN1 was deposited in the 
pericellular matrix of N-cadherin+ cells (Figure 4A and 
4B). Generation of EPCAM¯/NCAM+ cells is the earliest 
stage of mesoderm commitment from undifferentiated 
human embryonic stem cells [26]. Analysis of this dataset 
(GSE21668) revealed de novo HAPLN1 expression at 
the earliest stages of mesoderm commitment (Figure 
5A). Consistently, by real-time PCR, fibroblast-like 
HCC 3SP cells showed higher HAPLN1 mRNA levels 
than epithelial 3P cells (Figure 5B). Moreover, kinetics 
analysis of gene expression, upon dedifferentiation of 
hepatocyte-like HepaRG cells to transient mesenchyme-
competent progenitors, revealed that HAPLN1 became 
detectable at 24 h and increased by 8 folds at 48 h 
post plating. Conversely, upon differentiation of these 
progenitors to hepatocyte-like cells, HAPLN1 decreased 
by >35 folds from day 4 to day 15 and was no longer 
detectable thereafter. This expression kinetics was similar 
to those of COL4A1 and LGR5 (Figure 5C). Furthermore, 
transfection of HepaRG progenitor cells with HAPLN1 
siRNA downregulated the mesenchymal markers Snail, 
α-SMA, collagen type IV and the stem cell marker 
LGR5. Snail was also downregulated by β-catenin and 
LGR5-targeting siRNAs (Figure 6). Taken together, these 
findings indicate that HAPLN1 hallmarks mesenchymal 
commitment of hepatic progenitors. 
HAPLN1 is expressed at high levels in a subset of 
HCCs with bad outcome after curative resection.
HAPLN1 mRNA levels were measured by real-time 
PCR in 82 HCCs from 70 patients, 5 histologically normal 
liver controls, 11 FNHs and 66 matching non-tumor liver 
samples. HAPLN1 was detected at much higher levels 
in HCCs than in non-tumor livers in our cohort (Figure 
7A), as well as in 80 HCCs with respect to 307 non-tumor 
hepatitis/cirrhosis livers in a public DASL microarray 
dataset (GSE10143) [12] (Figure 7B). 
The clinical and biological features of the HCC 
patients in our cohort and the flowchart of inclusion 
criteria for survival analysis are detailed in Supplementary 
Table 8, A and B. A binary HAPLN1 expression score 
was generated from our real-time PCR and TMA 
immunohistochemistry data. HAPLN HIGH and LOW 
HCCs showed significantly different HAPLN1 mRNA 
levels and TMA immunohistochemistry scores (Figure 7C 
and 7D). HAPLN HIGH patients presented lower disease-
free and overall survival (Figure 7E and 7F). Univariate 
Cox’s analysis (Supplementary Table 9) confirmed the 
association of HAPLN1 with poor survival after curative 
resection. Multivariate analysis after adjustment for alpha-
fetoprotein, vascular invasion, number of resected liver 
segments and capsular infiltration by the HCC showed that 
HAPLN1 was independently associated with survival after 
curative resection, with a mean increase in relative risk 
of 4.6 folds (Figure 7G). Of note, HAPLN1 relationship 
with survival was not dependent on β-catenin exon 3 
mutations (Figure 7H) assessed by Sanger sequencing 
(Supplementary Table 10). Indeed, HAPLN1 expression 
was not driven by β-catenin activating mutations 
(Supplementary Figure 3). This contrasts with LGR5 
(Supplementary Figure 3), which expression may be 
governed by both β-catenin mutations [1, 2] and by Wnt-
driven stem cell amplification [13]. 
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Figure 4: HAPLN1 upregulation by Wnt3a over 13 days. HepaRG progenitor cells were cultured with control FCS(-)/BSA(+) 
or FCS(-)/BSA(+)/Wnt3a. A. HAPLN1 mRNA levels 12 h and 13 days upon Wnt3a-induction. B. Immunodetection of HAPLN1, red 
(Cy5); N-cadherin, green (FITC). Nuclei, blue (DAPI). Images acquired at 20X. Control (BSA) shows very rare cells expressing HAPLN1 
(arrow). HAPLN1 labels the pericellular matrix and colocalizes with N-cadherin. 
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Figure 5: HAPLN1 hallmarks early mesoderm commitment of pluripotent hES cells and spontaneous EMT. A. 
Normalized mRNA data from GSE21668 [26] showing de novo HAPLN1 expression in early EPCAM¯/NCAM+ mesoderm-committed 
progenitors generated from undifferentiated human embryonic stem cells. B. HAPLN1 expression analyzed by real-time PCR in the 
3P→3SP human HCC cell lines derived from the same tumor. Mesenchymal 3SP result from epithelial 3P cells that underwent spontaneous 
EMT [23]. C. Kinetics of mRNA expression analyzed by real-time PCR in HepaRG cells along the retrodifferentiation of hepatocytes into 
liver progenitors and the differentiation of liver progenitors to hepatocytes. Time points 0 h and 30 days (COL4A1 and LGR5) or 15 days 
(HAPLN1) were used as calibrators. HAPLN1 was not detectable at 30 days in differentiated hepatocyte-like cells. 
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Figure 6: HAPLN1 silencing leads to mesenchymal and stem cell marker loss. Real-time-PCR-assessed mRNA expression of 
the indicated genes in HepaRG progenitor cells transfected with the indicated siRNAs. HAPLN1 silencing downregulates SNAI1; ACTA2; 
COL4A1 and LGR5 expression. 
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Figure 7: High HAPLN1 expression indicates bad outcome after curative HCC resection. A. Real-time PCR analysis of 
HAPLN1 mRNA expression in HCC, histologically normal liver controls C, focal nodular hyperplasias FNH and matching non-tumor 
livers NT. Controls were used as calibrator. Asterisks (***) indicate P<0.001 for NT versus HCC. B. Comparison of HAPLN1 mRNA 
levels in HCC versus NT from a public DASL microarray dataset (GSE10143) [12] normalized by the cubic spline algorithm and filtered 
by fold change (up/down>3). C. and D. HAPLN1 LOW and HAPLN HIGH classes display different mRNA and protein levels by real-
time PCR and by TMA-based immunohistochemistry scoring. E. and F. Disease-free and overall survival after curative HCC resection. 
The number of patients at risk at each time point is shown (Upper row, HAPLN LOW; lower row, HAPLN1 HIGH). G. Multivariate Cox’s 
proportional hazards model after adjustment for alpha-fetoprotein, vascular invasion, number of resected liver segments and capsular 
infiltration. The model indicates that HAPLN1 is independently associated with survival. H. Cox’s model integrating β-catenin (CTNNB1) 
exon 3 mutations shows that HAPLN1 is not dependent on β-catenin mutations.
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HAPLN1 emerges in aggressive HCCs expressing 
markers of tumor stem/progenitor cells
HCCs showed co-expression of HAPLN1 with 
other genes found to be induced by Wnt3a in vitro. 
HAPLN1 and the tumor progenitor cell markers CD44 
and LGR5 were detected in tumor cells at the tumor-
stroma interface and in cells arranged in an “Indian 
file” pattern (Figure 8A). HAPLN1 correlated with 
laminin ɣ1, α-SMA, CD44, as well as with other genes 
induced by Wnt3a, such as LFNG, IGFBP5, LEF1 and 
PI15 (Figure 8B). HCCs with microscopic vascular 
invasion had high mRNA levels of HAPLN1, LGR5, 
LEF1, SOX9, CD44, Glypican 3 and larger tumor size 
(Figure 8C). Serum AFP levels were higher in HAPLN1 
HIGH class patients and, similarly, patients with high 
AFP levels displayed high immunohistochemistry scores 
for HAPLN1. Likewise, high HAPLN1 expression 
correlated with the stem cell marker PROM1 and 
with cytoplasmic β-catenin (Figure 8D). Consistently, 
cytoplasmic β-catenin staining is increased in HCCs 
showing enhanced Wnt signaling without β-catenin 
gene mutations [1, 2]. Moreover, a cluster of biomarkers 
induced by Wnt3a in HepaRG cells reflecting progenitor 
cells with mesenchymal commitment was associated with 
high Edmondson-Steiner’s score in HCCs, indicating poor 
tumor differentiation (Supplementary Figure 4). Taken 
together, these findings indicate that HAPLN1 emerges in 
mesenchymal-committed tumor progenitor cells driving 
tumor aggressiveness and poor outcome in HCC. 
DISCUSSION
We show here that Wnt-specific signals foster 
fibrogenic, myofibroblast-like populations with stem 
cell features and impair hepatocyte and biliary lineage 
commitment of liver progenitors. The pathway crosstalks 
elicited by Wnt-specific signals form a tight network 
in HCCs. Among the genes switched on within this 
network, HAPLN1 is associated with bad outcome and 
with the expression of markers of stemness and of tumor 
aggressiveness (Figure 9). 
We showed that Wnt3a upregulates TGFB1, 
TGFB2 and BMP1 expression. In turn, TGFB activates 
Wnt signaling and plays a key role in mesenchymal 
commitment [4, 27]. Thus, Wnt/TGFB pathways 
may set up a positive feedback loop leading to tumor 
aggressiveness. In addition, R-spondin binding of LGR5 
receptors enhances Wnt signaling and leads to long-term 
expansion of bipotent hepatic progenitor cells [13]. In 
this context, excess of TGFB/BMP signaling is inhibited 
by Noggin, thus avoiding growth arrest and epithelial-
mesenchymal transition [13, 28]. Our data suggest that 
Wnt3a triggers finely-tuned signaling pathway crosstalks, 
driving progenitor cell reprogramming to replicative, 
invasive and fibrogenic myofibroblast-like cells. Probably 
because Wnt3a upregulates Noggin (Figure 3A and 3F), 
as well as MYC and BIRC5 (Figure 1C), TGFB/BMP 
signaling is counterbalanced, thus avoiding growth arrest 
and achieving high proliferation rates throughout a two-
week assay (Figure 1F). Despite their fibrogenic activity, 
these myofibroblast-like progenitors kept high levels of 
the stem cells markers CD44 and LGR5. Thus, the rates 
of proliferation and the expression of stem cell markers 
suggest that these cells are not terminally differentiated. 
This phenotype is compatible with the dynamics of cancer 
progression. 
Wnt/β-catenin lies at the crossroads of a growing 
list of signaling pathways, including Hedgehog and 
Notch [5, 29]. High LGR5 expression was achieved 
through Wnt3a induction of Indian Hedgehog. As both 
Wnt [13] and Hedgehog [30] pathways upregulate LGR5 
expression, Wnt/Hedgehog cross-talks probably amplified 
the LGR5+ stem cell population. Along these lines, Notch 
signaling leads to biliary lineage commitment [28], 
but Wnt3a reduced Notch2 expression (Figure 1C) and 
upregulated the Notch inhibitor LFNG (Figure 3, A), thus 
impairing biliary lineage commitment. The Wnt-triggered 
signaling network also included insulin growth factor 
pathway members, namely IGFL1; 2 and 3, IGF2BP3 
and FHL2. IGF2BP3 is an oncofetal IGF-mRNA-binding 
protein de novo expressed and promoting aggressiveness 
in HCC [31]. FHL2 enhances β-catenin-dependent 
transcription of IGFBP5 [32]. IGFBP5, in turn, increases 
the bioavailability of IGF1 and IGF2 [33] and induces 
fibrogenesis [34]. 
Activation of Wnt signaling was reported in hepatic 
stem cell-like HCCs expressing the epithelial cell adhesion 
molecule EPCAM [35]. We found that the cancer epithelial 
cell markers EPCAM and cytokeratin 19 (KRT19) were 
highly correlated in 79 HCCs (R=0.87, Supplementary 
Table 7). However, neither EPCAM nor KRT19 did 
integrate the coexpression network of mesenchymal-
committed hepatic progenitors. Consistently, the earliest 
mesoderm-committed progenitor cells derived from 
human embryonic stem cells and mesenchymal-competent 
HepaRG progenitors are EPCAM¯ [18, 26]. As EPCAM+ 
HCC cells are epithelial [35], and our work is based on 
mesenchyme-competent EPCAM¯ hepatic progenitors 
[16, 18], we hypothesize that Wnt signals may direct 
transit-amplifying progenitor cells toward a mesenchymal 
phenotype. Importantly, through activation of different 
gene networks, both works show that the final output is 
enhanced tumor aggressiveness. 
Wnt signals led cells to ectopically express 
mesenchymal progenitor genes like HAPLN1, which 
regulates cell growth in developing cartilage [19] and 
heart valves [36]. Similarly, IGFBP5 and PI15 are 
involved in branching morphogenesis of epithelial organs 
[37]. In addition, HAPLN1 was expressed de novo upon 
mesenchymal commitment of embryonic stem cells 
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Figure 8: HAPLN1 is detected in HCCs featuring stem cell markers, high alpha-fetoprotein levels, vascular invasion 
and β-catenin activation. A. Immunodetection of HAPLN1, CD44 and LGR5 in formalin-fixed, paraffin embedded HCCs. Brown 
color, specific signal; blue, hematoxylin counterstaining. The three proteins are detected in tumor cells at the tumor-stroma interface (black 
arrows) and in cells arranged in “Indian files” (red arrowheads). B. Heatmap showing associations of HAPLN1 mRNA expression with the 
indicated genes. White bars indicate missing data (n=8/729 spots). Pearson’s X2 and Gamma correlation coefficients are shown on the right. 
C. Vascular tumor invasion (black squares) is associated with the indicated variables. D. Serum AFP levels are higher in HAPLN1 HIGH 
patients. High HAPLN1 protein correlates with high AFP serum levels. High PROM1/CD133 protein is detected in HAPLN1 HIGH HCCs. 
High HAPLN1 mRNA correlates with high cytoplasmic β-catenin. 
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and in two models of liver EMT. Conversely, HAPLN1 
knockdown in hepatic progenitor cells downregulated 
LGR5, α-SMA, collagen IV and Snail. In HCCs, in 
consistency with in vitro data, high HAPLN1 levels 
were associated with basement membrane remodeling, 
myofibroblast activation and expression of the stem/
progenitor markers CD44, LGR5 and CD133/PROM1; 
the Notch pathway inhibitor LFNG, the Wnt target gene 
LEF1 and the IGF pathway agonist IGFBP5 (Figure 8). 
Supporting our data, a bioinformatics study predicted 
HAPLN1 expression to lie downstream upregulated 
Wnt/β-catenin signaling in colorectal cancer [38] and 
proteomics analysis of tumor stroma reported HAPLN1 
in highly metastatic melanomas [25]. Also, HAPLN1 has 
been associated with bad outcome in pleural mesothelioma 
[39]. 
In conclusion, Wnt-specific signals led hepatic 
progenitors to specialize into invasive, proliferating 
myofibroblast-like fibrogenic cells with stem cell features 
through a subtle equilibrium of signaling pathway 
crosstalks. Through the ectopic induction of mesenchymal 
progenitor genes in liver cancer cells, Wnt signals confer 
a high degree of biodiversity and, ultimately, selective 
advantages for cancer progression. 
MATERIALS AND METHODS
Patients, clinical data management and tissue 
banking 
Seventy HCC patients undergoing liver surgery 
with curative intention at Rennes University Hospital 
between January 1992 and December 2007 were included. 
Fifty-one were treated by partial hepatectomy and 19 by 
orthotopic liver transplantation (OLT). The microscopic 
features of tumors diagnosed as HCC were reviewed 
and annotated by a senior pathologist (BT). Combined 
hepatocellular-cholangiocarcinoma or fibrolamellar 
HCCs were not included. Demographic, clinical and 
biological data were retrieved from hospital charts by two 
experienced liver surgeons (LS & DB) and are described 
in Supplementary Table 8A. After resection, patients were 
followed up every 3 months for the first 2 years, and every 
6 months thereafter. Follow-up, which was available for 65 
patients, included clinical examination, serum AFP (alpha-
fetoprotein), ultrasonography and computed tomography. 
Mean and median follow-up times were 60 and 53 
Figure 9: Upon low density plating, hepatocyte-like cells acquire transient mesenchymal competence within 48 h and 
dedifferentiate to bipotent progenitors that normally re-differentiate into hepatocyte-like cells. A cell microenvironment 
enriched in Wnt signals reprograms liver progenitor cells into invasive fibrogenic myofibroblast-like cells within two weeks. These cells de 
novo express the cartilage gene HAPLN1 among other gene modulations. In HCCs, HAPLN1 is expressed de novo in a subset of patients 
presenting with HCCs that feature bad outcome, vascular invasion, high AFP serum levels and CD133+ tumor cells.
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months, respectively (95% CI= 50-70 months; range= 
3-150 months). The end of follow-up was set between 
June and September 2012 or at the time of death. Only 
patients undergoing partial hepatectomy, with a follow-
up ≥ 3 months and with complete tumor resection were 
included in the survival analyses. Early deaths, unrelated 
to the HCC, and patients without microscopically tumor-
free resection margins, as well as patients treated by OLT, 
were excluded from survival analyses. Survival analysis 
flowchart is shown in Supplementary Table 8B. Eighty-
two frozen tumors from 70 patients were analyzed. As 
controls, we included 66 matching non-tumor livers, 5 
histologically normal livers from patients undergoing 
resection of liver metastases of extrahepatic primary 
cancers and 11 focal nodular hyperplasias. Non-tumor 
and normal liver samples were obtained at >2 cm from 
the tumors. Frozen human tissue samples were obtained 
after processing by the Biological Resource Center (BRC) 
at Rennes University Hospital (BB-0033-00056). Briefly, 
fresh tissues were frozen at -80°C in N2-cooled isopentane 
and stored at -80°C under quality-controlled conditions. 
Formalin-fixed, paraffin-embedded tissue blocks were 
obtained from the Anatomic Pathology laboratory. The 
study protocol complied with French laws and regulations 
and fulfilled the requirements of the local institutional 
ethics committee. Sample collection was reported to the 
Ministry of Education and Research (No. DC-2008-338). 
Cell culture 
Huh-7 [8] and 3P/3SP [23] cells were cultured [10] 
and Wnt3a-enriched conditioned medium was collected 
as described [9, 10]. HepaRG cells were expanded as 
liver progenitors, differentiated to hepatocytes and 
retrodifferentiated to liver progenitors [18]. To induce 
EMT in HepaRG cells, progenitor HepaRG cells were 
detached by trypsinization, seeded at low density (2x104 
cells/cm2), detached three days later and seeded at the 
same density in complete HepaRG medium containing 
50% Wnt3a-conditioned or 50% control L cell medium. 
In other experiments, purified mouse recombinant Wnt3a 
(R&D Systems, 7nM) and/or mouse FZD8_CRD (30 
nM, R&D Systems) were added to serum-free HepaRG 
medium containing 0.1% BSA for the indicated periods 
of time according to the experiment. Independent culture 
experiments were performed in triplicate. 
Tissue-microarray (TMA) and immunohistochemistry 
scoring of human tissues
For selection of tissue blocs for TMA construction, 
the whole set of archival HE-stained sections from 
formalin-fixed, paraffin-embedded tissue blocks from 
each one of the 67 available HCC patients and from 
five histologically normal livers were reviewed (Nikon 
80i microscope) to ensure that the selected paraffin bloc 
was the mirror lesion of the frozen sample. A region of 
interest (ROI, 0.5 to 1 cm in diameter) was labeled with 
a permanent marker to precisely localize the punch zone. 
TMA construction was done with a MiniCore3 tissue 
arrayer (Alphelys, Plaisir, France). ROIs were punched 
in triplicate. Punch size was set at 1000 µm in diameter. 
HCC samples were randomly assigned to either one of 
two 132-punch receiver paraffin blocks. Randomization 
was performed with a “rand” function in Microsoft 
Excel. The five histologically normal liver controls were 
included in both array blocs #1 and #2 to control for 
signal and background intensities. Five-µm microtome 
sections were processed for immunohistochemistry 
with a Discovery XT from Ventana Medical Systems 
(Roche) slide staining system. See Supporting Table 2 
for antibodies used. Stained slides were converted into 
high-resolution digital data with a NanoZoomer digital 
slide scanner (Hamamatsu, Massy, France). Digital slides 
were viewed using NDP.view software (Hamamatsu) in a 
Dell S2415H 24-Inch Screen LED-Lit Monitor. The signal 
was independently read by two observers (RD and OM) 
who were blinded to any information. Discrepancies were 
resolved by consensus reading. A 4-point scale (0-1-2-
3-4) denoting increasing signal intensity was used. The 
relative importance of focal versus general expression of 
the proteins under study was weighted using the following 
formulas, where GS stands for general score and FS stands 
for focal score:
If general signal predominated, score = 2xGS + FS 
+ 1; (where +1 was used to weight the relative importance 
of general signal with respect to focal signal). 
If focal signal predominated, score = 2xFS + GS.
When applied, these formulas yielded scores 
varying from 3 to 13. 
Cell growth assays 
Cells were seeded at low density (5×103 cells per 
well in 96-well plates). HepaRG culture medium was 
supplemented with 5-bromo-2’-deoxyuridine (BrdU, GE 
Healthcare Lifesciences) for 1h30 and cells were fixed 
with 4% PFA. BrdU was detected with mouse anti-BrdU 
antibody (1:200, ab8152; Abcam) followed by anti-mouse 
IgG-DyLight 488 (1:500, 072-03-18-18, Eurobio, Les 
Ulis, France). Image acquisition and quantitation of BrdU-
incorporating cells were performed with a Cellomics 
ArrayScan VTI HCS Reader (Thermo Scientific). 
Cell invasion
Cell invasion was assessed in Matrigel-coated 
Boyden chambers (Transwell inserts, 8.0 µm pore size, 
Corning). After five days of culture following a routine 
passage, cells were detached, washed with PBS and 
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suspended in serum-free medium supplemented with 0.1 % 
BSA. Then, 1x105 cells were seeded in the upper chamber 
of the Transwell insert. The lower chamber was filled with 
800 µl of serum-free medium with or without recombinant 
mouse Wnt3a (R&D Systems). After 24 hr of incubation at 
37°C, cells were fixed with 4% PFA and stained with 2.3% 
crystal violet. Non-invading cells were gently removed 
from the upper surface of the insert and images from 
five fields per membrane were randomly acquired (Axio 
observer, Carl Zeiss microscopy). Quantitation of invading 
cells was done with ImageJ (NIH).
β-catenin exon 3 sequencing and search for 
β-catenin exon 3 deletions
For mutation analysis, exon 3 and the flanking 
intronic sequences of the CTNNB1 gene were amplified 
by PCR using Kappa HiFi DNA polymerase (Kapa 
Biosystems, Wilmington, MA). Briefly, 50 ng of genomic 
DNA were used as template with βCATEX2F (5’-GAA-
AAT-CCA-GCG-TGG-ACA-ATG-3’) and βCATEX4R 
(5’-TCG-AGT-CAT-TGC-ATA-CTG-TCC-3’) as 
oligonucleotide primers. The reaction included a 95°C 
denaturation step for 3 min followed by 35 cycles 
consisting of: 98°C denaturation for 15 sec, 60°C 
annealing for 15 sec, and elongation 72°C for 30 sec. Both 
strands of the amplified products were directly sequenced 
on an automated sequencer (ABI 3700; Perkin-Elmer, 
Boston, MA). Negative results on exon 3 mutations may 
overlook large exon 3 deletions in CTNNB1. Indeed, as 
somatic deletions are heterozygous, the wild-type allele 
may mask the deletion upon Sanger sequencing [40]. 
To avoid this pitfall, cases showing no exon 3 mutation 
were screened for β-catenin deletion by PCR on reverse-
transcribed tumor cDNA. For PCR amplification of 
the exon 3 of CTNNB1, oligonucleotide primers (F1: 
5’- GCG-TGG-ACA-ATG-GCT-ACT-CAA-G-3’; R1: 
5’- TAT-TAA-CCA-CCA-CCT-GGT-CCT-C-3’; and 
R2: 5’- TTC-AGC-ACT-CTG-CTT-GTG-GTC-3’) were 
used. The primer pairs F1-R1 and F1-R2 yielded 517 bp 
(169 aa) and 1043 bp (344 aa) amplicons, respectively. 
As positive control, HepG2-derived cDNA was used, as 
these cells harbor a large CTNNB1 deletion (amino-acids 
25-140) [40]. PCR was performed using the GoTaq Green 
Master Mix (Promega) and amplicons migrated in 1.5% 
Nusieve agarose (LifeTechnologies) gels. 
DNA microarrays 
In vitro transcription and labeling of 150 ng 
total RNA was carried out using an Agilent Low-Input 
QuickAmp Labeling kit (Agilent Technologies, Santa 
Clara, CA, USA) in the presence of Cy3-CTP following 
the manufacturer’s protocol. After purification using 
an RNeasy mini kit (Qiagen, Hilden, Germany), cRNA 
yield and specific activity were determined using a 
NanoDrop spectrophotometer, as previously described 
[10]. Equal amount of Cy3-labeled cRNA was subjected 
to fragmentation followed by 18-hr hybridization onto 
Agilent human 4x44K v2 pangenomic microarrays. 
Washing and scanning were performed according to the 
manufacturer’s instructions (Agilent Technologies). Gene 
expression data were further processed using Feature 
Extraction (version 10.7) and GeneSpring (version 11.0) 
softwares (Agilent Technologies). Filtration of array data 
resulted in the selection of nonflag-positive and significant 
gene features. Inter-array normalization was performed by 
using the 75th percentile signal value. Transcriptomic data 
have been deposited in NCBI’s Gene Expression Omnibus 
and are accessible through GEO Series accession number 
GSE68633. 
Functional genomics analyses
Hierarchical clustering was performed with the 
hclust function in R software, applying the Ward method 
to correlation-based distances. Gene annotations based 
on gene ontology and enrichment for biological functions 
were done with the FuncAssociate 2.1 program [21]. 
Gene ontology functions were summarized by removing 
redundant terms using REVIGO [41]. Ingenuity pathway 
analysis was used to identify top biological functions, 
upstream regulators and transcription regulators (Ingenuity 
Systems, Redwood City, CA, USA). Gene set enrichment 
analysis (GSEA) was performed with the web-based tool 
developed at the Broad Institute [42].
Statistical analyses
After removing experimental batch effect with 
the SVA package [43], gene networks were generated 
by Weighted Correlation Network Analysis (WGCNA, 
WGCNA package) [44] using expression data. Gene 
networks were visually integrated with Cytoscape, 
with a correlation coefficient threshold ≥0.30 [45]. To 
analyze patient data, the Recommendations for Tumor 
Marker Prognostic Studies (REMARK) were applied 
[46]. Briefly, to screen our transcriptomic dataset for 
biologically relevant genes warranting further studies, 
we focused on those meeting two criteria: (i) response 
to both β-catenin targeting siRNA and FZD8_CRD in 
independent experiments and (ii) involvement in key 
signaling pathways. Eight genes meeting these criteria 
were analyzed by real-time PCR and TMA-based 
immunohistochemistry in human HCCs. Complying 
with the REMARK guidelines [46], the inclusion 
criteria for survival analysis are shown by a flowchart 
in Supplementary Table 8B. Survival analyses were 
performed using the Log Rank test and Kaplan-Meier 
curves and the Cox’s proportional hazards method for 
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univariate or multivariate analyses, as indicated. To this 
end, real-time PCR results were calculated by the ΔΔCt 
method and calibrated with respect to the median of a 
standard range curve run in every experiment. Real-time 
PCR results were further normalized by the following 
equation: [(LNi-meanLNi→n)/SDLNi→n], where LN, natural 
logarithm; i→n, from the first to the last value. To obtain 
binary values for Kaplan-Meier curves, normalized real-
time PCR results were binarized using the median as the 
cut-off value. TMA-based immunohistochemistry scores 
(0-1-2-3-4) were binarized by a ≥3 cut-off score for focal 
expression of specific proteins. 
Correlation analyses between gene expression 
levels were performed with the Spearman rank order 
test (continuous variables, non-parametric distribution). 
Association analyses between binary or ordinal variables 
(expression scores, clinical, biological or anatomic 
pathology data) were performed with Pearson’s Chi2 or 
Fisher exact test. Group comparisons were done with 
non-parametric ANOVA and the Kruskal Wallis post 
hoc tests, unless otherwise indicated. Heatmaps showing 
associations between binary patient data were constructed 
with Excel (Microsoft Office 2010). Statistical calculations 
were performed with the R software (version 3.1.1) and 
the packages survival, FactoMineR, gplots, colorspace 
and marray or with Statistica 10 (Statsoft, Maisons-Alfort, 
France). 
See Supplementary Materials and Methods for: RNA 
interference, nucleic acid extraction from human tissues 
and cells, real-time PCR and immunocytochemistry. See 
Supplementary Table 1 for real-time PCR primers and 
TaqMan probes and Supplementary Table 2 for antibodies. 
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